Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Sk Pharmteco Begins Clinical Trial Production of Eli Lilly's Monthly Obesity Drug

Summary by 조선일보
SK Pharmteco, a contract development and manufacturing organization (CDMO) subsidiary of SK Group, has begun producing clinical-use active pharmaceutical ingredients (API) for Eli Lilly and Company's next-generation glucagon-like peptide-1 (GLP-1) obesity treatment. This API will be used in research into a long-acting formulation that can be administered once a month.

1 Articles

조선일보조선일보
Lean Right

Sk Pharmteco Begins Clinical Trial Production of Eli Lilly's Monthly Obesity Drug

SK Pharmteco, a contract development and manufacturing organization (CDMO) subsidiary of SK Group, has begun producing clinical-use active pharmaceutical ingredients (API) for Eli Lilly and Company's next-generation glucagon-like peptide-1 (GLP-1) obesity treatment. This API will be used in research into a long-acting formulation that can be administered once a month.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Right
100% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

조선일보 broke the news in on Tuesday, March 10, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Eli Lilly icon

Eli Lilly

Economy icon

Economy

GLP-1 icon

GLP-1

South Korea icon

South Korea

Business & Markets icon

Business & Markets

South Korea Economy icon

South Korea Economy

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal